Streetbeat News

ABVX

Abivax SA American Depositary Shares

https://www.abivax.com

Industry

Biotechnology

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Open

8.80

Mkt cap

551M

Volume

76K

High

8.80

P/E Ratio

-2.39

52-wk high

17.02

Low

8.51

Div yield

N/A

52-wk low

8.51

Abivax is set to present four abstracts on obefazimod for ulcerative colitis and a preclinical colon cancer model at Digestive Disease Week 2024. The presentations will cover new preclinical data demonstrating obefazimod's effectiveness in reducing tumor numbers in a mouse model, supporting its novel mechanism of action.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 8:18 am

Abivax shares have seen an increase in their trading value following bullish ratings from Guggenheim and Piper Sandler, indicating a positive outlook on the stock by these financial institutions.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 7:57 pm

Guggenheim analyst Yatin Suneja initiates coverage on Abivax (NASDAQ:ABVX) with a Buy rating and a price target of $50.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 10:22 am

Piper Sandler analyst Christopher Raymond has initiated coverage on Abivax (NASDAQ:ABVX) with an Overweight rating and set a price target of $42.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 9:39 am

Morgan Stanley analyst Vikram Purohit maintains an Equal-Weight rating on Abivax (NASDAQ:ABVX) and raises the price target from $15 to $16.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 11:29 am

Earnings reports for April 2, 2024, include a mix of expected profits and losses across various sectors. Notable companies like Paychex and Cal-Maine Foods anticipate earnings, while others like Allego and AIM ImmunoTech project losses. This diverse set of earnings could indicate sector-specific movements in the market.

Portfolio Pulse from Benzinga Insights

April 02, 2024 | 10:25 am

Abivax reported a FY23 net loss of €147.4 million, a significant increase from the previous year's loss of €60.7 million. However, the company maintains a strong cash position of €261 million.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 8:06 am

Abivax is set to host a KOL investor event on February 6 to discuss Phase 2B data and Phase 3 trial design for Obefazimod, a treatment for moderately to severely active ulcerative colitis.

Portfolio Pulse from Benzinga Newsdesk

January 24, 2024 | 10:36 am

Leerink Partners analyst Thomas Smith has initiated coverage on Abivax (NASDAQ:ABVX) with an Outperform rating and set a price target of $20.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:11 pm

Morgan Stanley analyst Vikram Purohit has initiated coverage on Abivax with an Equal-Weight rating and set a price target of $15. Abivax is listed on NASDAQ under the ticker ABVX.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 1:09 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.